Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sunesis has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Sunesis, 2018, MAR 9, 2018, View Source [SID1234524608]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 9, 2018 – Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, reported the upcoming release of financial results for the three months ended January 31, 2018, to take place on Monday, March 12, 2018 (Press release, Advaxis, MAR 9, 2018, View Source [SID1234524599]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Advaxis’ senior management will host a conference call to review its financial results and provide a business update. The conference call and live audio webcast will begin at 4:30 p.m. Eastern time on Monday, March 12, 2018.

Conference Call & Webcast Information
WHEN: Monday, March 12, 2018 at 4:30 p.m. Eastern time.
DOMESTIC DIAL-IN: (844) 348-6133
INTERNATIONAL DIAL-IN: (631) 485-4564
CONFERENCE ID: 2588455
WEBCAST: ir.advaxis.com/events-presentations

For those unable to participate in the live conference call or webcast, a digital recording will be available beginning March 12, 2018 two hours after the close of the conference call. To access the recording, dial (855) 859-2056 or (404) 537-3406 and provide the operator with the conference ID: 2588455. In addition, the audio webcast will be archived on the Company’s website for a period of time at ir.advaxis.com/events-presentations/events-calendar.

Puma Biotechnology has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Puma Biotechnology, 2018, MAR 9, 2018, View Source [SID1234524630]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 9, 2018 -AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, reported the presentation of in vivo preclinical data showing AB-PA01 reduces biofilm in a Pseudomonas aeruginosa preclinical model (Press release, AmpliPhi Biosciences, MAR 9, 2018, View Source [SID1234524600]). The data were presented at the Australian Society of Otolaryngology Head and Neck Surgery 68th Annual Scientific Meeting, being held March 9-11, 2018 in Perth, Western Australia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, titled "Efficacy and safety of a Pseudomonas aeruginosa bacteriophage cocktail in a sheep model of rhinosinusitis" will be delivered by Dr. Stephanie Fong on Saturday, March 10, 2018, at 1:40 p.m. local time in Crown Ballroom 1, Concurrent Session 10 – Rhinology, at the Crown Perth Convention Centre.

"The data presented demonstrate the potential of bacteriophage therapeutics by clearly showing AB-PA01’s effectiveness in reducing biofilm in vivo, a major obstacle in the treatment of Pseudomonas aeruginosa and its associated symptoms," said Peter-John Wormald, M.D., Professor of Otolaryngology Head & Neck Surgery at the University of Adelaide and Principal Investigator for AmpliPhi’s already completed Phase 1 study, "I believe bacteriophage therapeutics hold much promise and this study adds to the growing body of supportive evidence."

A sheep rhinosinusitis model was adapted to simulate Pseudomonas aeruginosa infection in sheep frontal sinuses. To assess efficacy, after a 7-day biofilm formation period, sheep received twice-daily flushes of AB-PA01 or saline for one week. Biofilm quantitation on the frontal sinus mucosa was performed using BacLight LIVE/DEAD stain. The study showed a statistically significant reduction in biofilm biomass with AB-PA01 compared to control (p<0.05). No safety concerns were noted